Grown Rogue International (GRUSF) Cash from Restructuring (2015 - 2020)
Grown Rogue International (GRUSF) posted quarterly Cash from Restructuring of -$70425.0 for Q2 2020, down 4.76% quarter-over-quarter from -$67225.0 in Q1 2020.
Grown Rogue International (GRUSF) Cash from Restructuring (2015 - 2020) Analysis & Trends
Grown Rogue International's Cash from Restructuring history runs 3 years deep, the most recent figure standing at -$70425.0 for Q2 2020.
- In Q2 2020, Cash from Restructuring changed N/A year-over-year to -$70425.0; the TTM figure through Apr 2020 stood at -$407584.0 (down 111.24% YoY), while the FY2019 annual figure was $3.5 million, changed N/A from the prior year.
- Cash from Restructuring for Q2 2020 stood at -$70425.0, down from -$67225.0 in the prior quarter.
- The five-year high for Cash from Restructuring was $3.7 million in Q1 2019, with the low at -$269934.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Grown Rogue International | 109.32 Mn | 97.78 Mn | 5.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2020 | -70,425.00 |
| Jan 31, 2020 | -67,225.00 |
| Oct 31, 2019 | -269,934.00 |
| Jan 31, 2019 | 3.72 Mn |
| May 31, 2015 | -97,071.87 |